


Lyphosot®

A unique medicine
for the lymphatic system



Safe and effective for:



- *Lymphoedemas of various origins*
- *General susceptibility to infections*
- *Hypertrophy of the lymphatic organs*
- *Glandular swelling*
- *Tonsillar hypertrophy and chronic tonsillitis*
- *Diabetic polyneuropathy*

-Heel®

Biologische Heilmittel Heel GmbH
Baden-Baden, Germany

Over 40 years of worldwide therapeutic use by:

- Homeopaths
- Naturopaths
- Chiropractors
- General Practitioners
- Dental surgeons
- Plastic surgeons
- Veterinary doctors

The importance of the lymphatic system

No other system has been as frequently underestimated in its importance as the lymphatic system. Only recently, in the last two decades, scientific research conducted in the field of cancer and immunology as well as histological developments (eg. Pischinger's ground system) underlined the key importance of the lymphatic system. Once seen as a mere transportation system for fluids and plasma proteins, it is now recognized that the lymphatic system also contributes actively to the detoxification of the organism in addition to playing an important role in the human defense system.

Safe and effective drugs for exerting a therapeutic influence on the lymphatic system are rather scarce. Yet there is a clear need for such preparations;

lymphoedema, for example, is among the most common lymph pathology and current treatments are seldom successful. Similarly, chronic diseases of the lymphatic organs, such as chronic tonsillitis, are also frequent in the physician's practice, and ultimately treated through surgical removal of the inflamed tissues with unknown long-term effects on the overall immune system of the patient. Similarly, a weakened functionality of the lymphatic organs is frequently expressed as a general susceptibility to infections.

Lyphosot is one such preparation that safely and effectively stimulates the lymphatic organs and supports the detoxification function of the lymphatic system.

Pharmacological description

Lyphosot promotes continual interstitial drainage and hence, the outflow of pathological metabolites.

Lyphosot stimulates the efficiency of the lymphatic organs which, in turn, strengthen the body's own immune system.

Lyphosot regulates the pathologically-induced changes in the relationship between the lymphatic payload and lymphatic flow rate.

Lyphosot is a prerequisite for the treatment of chronic diseases.

Lyphosot has proven effective in treating lymphoedema as well as lymphatism (status lymphaticus).

Lyphosot is suitable for all patients, including children, pregnant or breast-feeding women, and multi-morbid patients.

Lyphosot is compatible with allopathic medication (no known interactions).

Lyphosot is without any known side effects, and can be used on a long-term basis.



Lyphosot®

Tested clinically

Efficient in lymphoedemas, infections and inflammations

In a multicentre observation study involving 3,512 patients and 264 doctors, Zenner and Metelmann¹ reported the efficacy of Lymphomyosot* in a wide range of indications including lymphoedemas of various origins (Fig.1), inflammatory or infectious conditions of the upper respiratory tract (Fig.2) and general susceptibility to infections (Fig.3).

In acute diseases, the average duration of treatment was approximately 1-3 weeks, whereas treatment lasted from 1-3 months in chronic and recurrent conditions, sometimes for as long as 6 months.

Figure 1: Results of therapy with Lymphomyosot* in lymphoedemas (n=684)




Figure 2: Results of therapy with Lymphomyosot* in tonsillitis, other infections of the ENT area and tonsillar hyperplasia (n=1244)





Figure 3: Results of therapy with Lymphomyosot* in lowered resistance (general susceptibility to infection) (n=319)



In addition to being compatible with a variety of other therapeutic strategies, Lymphomyosot* has been successfully used to treat a wide variety of inflammatory acute and chronic conditions such as sinusitis or tonsillitis².

As a prophylactic treatment of recurrent tonsillitis

Lymphomyosot has also proven its efficacy as a prophylactic treatment against recurrence of tonsillitis among children. During the two observation periods of 12 weeks over two consecutive winters, episodes of tonsillitis became less frequent and less severe with the administration of Lymphomyosot*. 17 patients (out of 37 patients) had no recurrence of tonsillitis at all during the second winter and 7 patients suffered from no illness whatsoever over the entire period of the study (both winters) after the initial tonsillitis has subsided³.

Superior to α -lipoic acid in treating polyneuropathy of diabetes type II

In a recent prospective, multi-centered, reference-controlled cohort study, Lymphomyosot* was compared with α -lipoic acid, the standard therapy for the polyneuropathy of diabetes mellitus type II⁴. This study was carried out on 90 patients over a 8-month period. A first group of patients received Lymphomyosot, a second group received both Lymphomyosot and α -lipoic acid, while a third group was given only α -lipoic acid. Color sonography and nuclear magnetic angiography (in selected cases) were used for the diagnosis of vascular lesions. Oedema and impairment of sensitivity were determined by palpation and sensitivity tests according to Rydell and Seifer.

In addition to reducing oedema and pain (in 75% of patients), Lymphomyosot* was shown to be superior to the treatment with α -lipoic acid alone in improving sensitivity. Furthermore, when used in combination with the α -lipoic acid, Lymphomyosot* improved the utilization of the α -lipoic acid at the nerve cells resulting in a maximum improvement of sensitivity.

According to this study, the known risks related to diabetes type II can be reduced and the prognosis for the vascular, lymph and neuronal disorders, improved through lymph therapy using Lymphomyosot* in addition to the standard therapy with α -lipoic acid.

* The name of the preparation in Germany is Lymphomyosot .

References

- Zenner, St. and H. Metelmann. Therapeutic Use of Lymphomyosot - Results of a Multicentre Use Observation Study on 3,512 patients. Biological Therapy, June 1990, Vol.VIII, No.3, p. 49 and October 1990, Vol.VIII, No.4, p.79.
- Riley, D. and S. White. A Biotherapeutic Approach to the Treatment of Inflammatory Disorders: A Drug Monitoring Trial. Biological Therapy, June 1992, Vol. X, No.3, pp.267-271.
- Rinneberg, A.L. The therapy of Tonsillitis and Prophylaxis against its Recurrence. Biological Therapy, Vol. IX, No.1, January 1991, pp.111-114.
- Dietz, A.R. Possibilities for a Lymph Therapy with Diabetic Polyneuropathy reprint translated from Biologische Medizin, 2000, 29(1): 4-9.

Ingredient	Pharmacological application
Lymph specific components	
Calcearia phosphorica	Constitutional ingredient for lymphadenitis
Juglans regia	Inflammation of the lymph nodes, lymphatism
Myosotis arvensis	Lymphadenitis (exudative diathesis), chronic bronchitis
Scrophularia nodosa	Inflammation and swelling of the lymph glands and breasts, frailty, hardening of the glands
Teucrium scorodonia	Chronic inflammation of the respiratory tract
Drainage components	
Apis mellifica	Edema with a pale, pasty appearance, inflammation with burning and stabbing pains
Equisetum hyemale	Cystitis, cystopyelitis, nephrolithiasis
Fucus vesiculosus	Scrofulous glandular swelling, struma, adiposis
Fumaria officinalis	Functional disorders of the liver, eczema, blood purifying agent in excessive homotoxin levels
Gentiana lutea	Chronic gastritis, flatulence, diarrhea
Geranium robertianum	Diarrhea, hemorrhages, painful micturition, ulcerations
Natrum sulphuricum	Chronic hepatopathy, gastroenteritis, asthma
Pinus sylvestris	Rickets, scrofulosis, bronchitis
Sarsaparilla	Irritating herpes, infantile facial eczema, increasingly painful micturition, gravel, cystitis, nephritis
Urtica urens	Urticaria, irritating dermatosis, uric acid diathesis
Veronica officinalis	Chronic bronchitis, cystitis, dermatoses



Lyphosot®

Lyphosot®

Drops / DIN 02229573

Tablets / DIN 02229577

Indications: Lymphatism (tendency to hypertrophy of the lymphatic organs; tendency to formation of edemas and susceptibility to infection); glandular swelling; tonsillar hypertrophy; chronic angina tonsillaris.

Contraindications: This preparation includes an iodine-containing ingredient. In cases of thyroid disorders with reduced iodine tolerance, use only following the advice of a physician.

Dosage: Drops: Adults: In general, 15–20 drops 3 times daily.

Tablets: Adults: In general, 3 tablets to be dissolved in the mouth 3 times daily.

Package sizes: Drops: Drop bottles containing 30 ml.

Tablets: Packs containing 50 tablets.

Viral infections of the upper respiratory system protocol, e.g. Mononucleosis

Week 1

• **3 x 3 Lyphosot tablets per day**

3 in the morning

3 at midday

3 in the evening

• **3 x 1 Engystol tablet per day**

1 in the morning

1 at midday

1 in the evening

Week 2

• **3 x 2 Lyphosot tablets per day**

2 in the morning

2 at midday

2 in the evening

• **3 x 1 Engystol tablet per day**

1 in the morning

1 at midday

1 in the evening

Week 3

• **3 x 1 Lyphosot tablet per day**

1 in the morning

1 at midday

1 in the evening

• **3 x 1 Engystol tablet per day**

1 in the morning

1 at midday

1 in the evening

Updated April 2002

The information contained in this document is meant for professional use only and is not intended to diagnose or treat any illness, nor is intended to replace competent medical advice. Heel® will not accept any medical or legal responsibility for misinterpretation or misuse of the informational and educational content of the present document.

Why should you use/ recommend Lyphosot®?

- ▶ A unique and effective preparation for the lymphatic system
- ▶ Wide range of therapeutic applications (acute and chronic conditions)
- ▶ For the treatment of lymphoedemas of various origins, inflammatory or infectious conditions of the upper respiratory tract and general susceptibility to infections
- ▶ Suitable for the majority of patients including children, pregnant and breast-feeding women, and multi-morbid patients
- ▶ Suitable for long-term therapy and well-tolerated
- ▶ Compatible with other medications, including allopathic therapies
- ▶ No known side-effects

-Heel®

Heel Canada Inc.

For more information please contact the exclusive distributor of Heel® in Canada:

Heel Canada Inc.
Montreal, Quebec, Canada

Tel.: (514) 353-4335

Fax: (514) 353-4336

Toll free

Tel.: **1-888-879-4335**

Fax: **1-877-353-4336**

E-mail: info@heel.ca

Web site: www.heel.ca